RxDoctor Payments DataLook up a doctor →

Dharmendra Patel, MD

Cardiovascular Disease · Jonesboro, ARNPI 1942262571

Payments from drug & device makers

$170,928in general payments, 2019–2025

Across 798 payments — averaging $214.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • American Regent$118K
  • Medtronic$20K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$10K
  • Boehringer Ingelheim International GmbH$7K
  • Pfizer$6K
  • Abbott$3K
  • plus $7K from 37 others

What the payments were for

  • Speaking & faculty fees$5,05014%
  • Travel & lodging$10,85230%
  • Food & beverage$20,42056%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$170,928 in reported general payments places this provider in the 90th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$367,397
Medicare patients
1,400
Services billed
4,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban330$227,770
JardianceEmpagliflozin85$54,979
EntrestoSacubitril/Valsartan58$47,989
XareltoRivaroxaban34$26,288
BrilintaTicagrelor37$17,098
Repatha SureclickEvolocumab16$17,027
Diltiazem 12hr ErDiltiazem Hcl13$5,894
Ranolazine ErRanolazine77$4,385
SotalolSotalol Hcl248$4,352
ClopidogrelClopidogrel Bisulfate463$4,132
Metoprolol Succinate375$3,711
Isosorbide Mononitrate ErIsosorbide Mononitrate230$2,286
Atorvastatin Calcium235$1,828
Diltiazem 24hr Er (Cd)Diltiazem Hcl79$1,496
Carvedilol208$1,318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$6,098$227,770330 claims
Boehringer IngelheimJardiance$459$54,97985 claims
NovartisEntresto$1,080$47,98958 claims
Johnson & JohnsonXarelto$465$26,28834 claims
AstraZenecaBrilinta$395$17,09837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →